Back to Search Start Over

Detrimental effects of performance-enhancing drugs on the heart: a case report of anabolic steroid induced cardiomyopathy.

Authors :
Gašparini, Dora
Klarić, Igor
Ivaniš, Viktor
Samsa, Dijana Travica
Peršić, Viktor
Wensveen, Tamara Turk
Source :
Cardiologia Croatica. Nov/Dec2023, Vol. 18 Issue 11/12, p308-309. 2p.
Publication Year :
2023

Abstract

Introduction: Synthetic anabolic androgenic steroids (AAS), compounds mimicking the action of endogenous testosterone in enhancing training performance, have been extensively studied during the last century. AAS abuse has become a major public health concern with an estimated worldwide lifetime prevalence of 1–5%1 . Long-term administration of AAS in supraphysiological doses may have detrimental effects on the cardiovascular system, presumably through direct action on cardiac myocyte androgen receptors. In severe cases, life-threatening conditions such as myocardial infarction, aortic dissection or cardiomyopathy, particularly dilated cardiomyopathy as the most common form, may occur. Hereby, we report a rare case of AAS-induced cardiomyopathy with an emphasis on the multidisciplinary approach. Case report: 46-year-old male bodybuilder presented with exercise intolerance unrelated to maximum training load and post-workout water retention 6 weeks before the visit. History revealed previous administration of testosterone enanthate 500 mg every 8 to 12 days during the period of 4 years. After a month-long cessation, he started taking testosterone undecanoate 1000 mg in 6-week intervals. The cardiorespiratory part of the physical examination showed normal findings and blood pressure of 125/80 mmHg. The patient was of athletic build with no signs of increased hairiness and no palpable testicular mass. An electrocardiogram showed a normal electrical axis and sinus bradycardia. Laboratory assessment (Table 1) was followed by echocardiography which was in accordance with the diagnosis of AAS-induced cardiomyopathy (Figure 1). Further diagnostic assessment of osteoporosis, hepatic, renal and psychological complications was performed. Conclusion: Long-term administration of AAS with unknown pharmacokinetic and pharmacodynamic properties should be considered as a cause of newly diagnosed cardiomyopathy, especially in previously healthy individuals with an athletic background. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1848543X
Volume :
18
Issue :
11/12
Database :
Academic Search Index
Journal :
Cardiologia Croatica
Publication Type :
Academic Journal
Accession number :
173376123
Full Text :
https://doi.org/10.15836/ccar2023.308